Reprint of "HHS Info Contradicts FDA on Plan B’s Abortifacient Nature," commentary published in LifeNews.com, March 16, 2012:
Washington, DC--A review of U.S. Dept. of Health and Human Services (HHS) documents on contraceptives raises questions as to why HHS is apparently:
(a) contradicting Food and Drug Administration (FDA) labeling in an HHS Office of Women’s Health document on emergency contraception, and–and whether ideological considerations are driving those decisions.
(b) leaving out vital information, in an HHS Office of Population Affairs document, about the drug’s post-fertilization, life-ending effect
A recently revised web-based fact sheet published by the HHS Office of Women’s Health appears to contradict FDA labeling on emergency contraception pills (levonorgestrel, also known as “Plan B,” “Plan B One-Step,” “Next Choice” and the “morning-after pill”). FDA labeling indicates that emergency contraception can end the life of a developing human embryo by preventing implantation.
The FDA notes, “Plan B One-Step is believed to act as an emergency contraceptive principally by preventing ovulation or fertilization (by altering tubal transport of sperm and/or ova). In addition, it may inhibit implantation (by altering the endometrium).”
In other words, the drug may prevent a living, developing human embryo from implanting in the womb, thus ending the life of the embryo. Because that information is a key concern for any women with pro-life conscience concerns, it must be presented to allow women fully informed consent in making their medical choices.
However, a recently revised version of the HHS Office of Women’s Health fact sheet casts the post-fertilization issue much differently than the FDA, asserting, “While it is possible that ECPs [emergency contraception pills] might work by keeping a fertilized egg from attaching to the uterus, the most up-to-date research suggests that ECPs do not work in this way.” The fact sheet does not provide any scientific references to back up what is asserted to be “the most up-to-date research.”
A previous version of the HHS Office of Women’s Health fact sheet had included a distinct section entitled, “How does emergency contraception work?” The previous fact sheet noted, “Emergency contraception can keep you from becoming pregnant by: Keeping the egg from leaving the ovary; OR Keeping the sperm from meeting the egg, OR Keeping the fertilized egg from attaching to the uterus (womb).”
The newly revised HHS document also refers readers for more information to (a) the FDA, (b) http://ec.princeton.edu/ and (c) Planned Parenthood. Both the original and revised HHS documents state that they were reviewed by James Trussell, PhD, Director of Office of Population Research at Princeton and a member of an FDA advisory panel that in 2003 recommended that Plan B be sold over the counter.
Another HHS fact sheet on emergency contraception, produced by the agency’s Office of Population Affairs, notes only that “Emergency contraception prevents pregnancy mainly by keeping the ovaries from releasing eggs. Emergency contraception also works by causing the cervical mucus to thicken, which blocks sperm from meeting with and fertilizing an egg.” The fact sheet does not mention at all the potential post-fertilization, life-ending effect of the drug.
Since 2002, the HHS Office of Public Health and Science has provided a process by which individuals and organizations can protest and request correction of wrong or incomplete public information disseminated by HHS.
The conspicuous omission of vital medical information needed to provide women with fully informed consent regarding emergency contraception, coupled with unsubstantiated assertions that contradict FDA labeling, lay the administration open to charges that it is advancing abortion ideology over science and violating President Obama’s barbed pledge in his inaugural address to “restore science to its rightful place.”
CMDA Ethics Statement: Abortion
Excerpted from "Pelosi on Obamacare: ‘Ironclad constitutionally,’ honors the ‘vows of our founders,’"
Excerpted from Senator Roy Blunt’s Statement On ObamaCare Supreme Court Hearings, March 26, 2012: “As the Supreme Court begins to hear arguments regarding the constitutionality of the President’s health care law, it’s clear to the majority of Americans that this burdensome and costly legislation is bad for families, seniors, and job creators.
CEO David Stevens, MD, MD (Ethics): "CMDA is working with the Bioethics Defense Fund and other groups, and we submitted an amici brief to the Supreme Court on an overlooked aspect of the Affordable Care Act (ACA) that includes an 'abortion premium mandate.'
President of Rare Genomics Institute, and CMDA Member Jimmy Cheng-Ho Lin, MHS, PhD: "Medicine is transforming right before our eyes. Recently, both Illumina and Life Technologies announced platforms to sequence human genomes for $1,000. In addition, Oxford Nanopore revealed its USB drive-sized disposable sequencer that will cost less than $900. With these new technologies and prices, genome sequencing is quickly becoming a reality as part of the healthcare system. Already, lives of children, such as Nic Volker at the Medical College of Wisconsin and the Berry twins at Baylor College of Medicine, have been dramatically transformed or even saved through this technology. While the age of genomic medicine is upon us, the ethical implications are still to be determined.
Senior Fellow for Life Sciences, Center for Human Life and Bioethics, and CMDA Member David A. Prentice, PhD: "The announcement of this conference on The Responsible Development of Nanotechnology is an opportunity for people to learn more about this developing technology. For those unfamiliar with nanotechnology, it involves fabrication of particles, including machines, that are microscopic or smaller (nano-scopic) in size. The older among us may remember the movie Fantastic Voyage, where a submarine and crew were shrunk to the size of a blood cell and injected into a patient; fans of Star Trek may think of the Borg, who injected nano-sized machines that remade the human body. While nanotechnology is not yet that advanced, there are already publications using nanoparticles to track and visualize specific cells; for vital imaging of tissues; cell-specific targeting of cancer chemotherapy and antibodies; gene delivery and expression in specific tissues; anofiber scaffolds for cell growth and tissue regeneration; and construction of molecular machines smaller than a human cell.
Director of Global Health Outreach Don Thompson, MD: "These nanotube-based diagnostics move us closer to Star Trek’s 'tricorder' multifunction handheld device. There are also DNA chip-based diagnostics in testing phases that have been developed by the military for use in rapid diagnosis; for example, to diagnose a fever of unknown origin in a patient who may have been exposed to an exotic natural or manmade pathogen. These technologies will go far to helping clinicians as the point of care in ruling out many potential diagnoses, and will help us focus on the unknowns.
CMDA Senior Vice President Gene Rudd, MD: "Res ipsa loquitur: quotes from the article by Giubilini and Minerva:
H. Patrick Stern, M.D. Professor of Pediatrics Chief, Section of Developmental/Behavioral ETSU Pediatrics: "Whether they are boys or girls, all children have some qualities of masculine and feminine behavior, with some displaying more evident behaviors of the opposite sex. Animal research demonstrates that animals castrated at birth and given physiological amounts of the hormone of the opposite sex will develop behaviors and physical characteristics of the opposite sex.